Reports related to this article:
Project(s): View 2 related projects in PECWeb
Released July 24, 2024 | GALWAY, IRELAND
en
Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--Johnson & Johnson (NYSE:JNJ) (New Brunswick) has announced that it will be spending a projected 580 million euro (US$622 million) on its Italian pharmaceutical operations.
Roughly 125 million euro (US$136 million) will go to capacity upgrades and a capability buildout at its Latina tablet manufacturing site in central Italy. Industrial Info is tracking two projects related to boosting capacity and new equipment additions. Latina plays a key role in Johnson & Johnson's global supply chain network, producing more than four billion tablets every year across 30 different products, with 97% of its production exported. The proposed projects will enable a production capacity increase of more than 25% and will include "innovative projects to support pipeline products and new production technologies", such as a Flex Line, which is designed to more efficiently handle the packaging of small production batches. There will also be a new continuous manufacturing line that will reduce total end-to-end manufacturing time and enable medicines to reach patients more quickly, the company stated.
Johnson & Johnson Innovative Medicine--formally Janssen--employs about 1,370 people in Italy. It said that its total Italian investment, which has included around 50 million euro ($54.6 million) in R&D over the past five years, has averaged 9.2% growth each year between 2019-2023 in Italy, "which is three times greater than the pharmaceutical sector average," it stated, citing a new study by The European House.
The investment was welcomed by the Italian Minister of Enterprises and Made in Italy Adolfo Urso: "Today's press conference demonstrates how the pharmaceutical sector has become a new growth model for Made in Italy, thanks to the impressive investments in research and innovation. This growth is 60% driven by foreign companies and allows the local supply chain to grow and promotes its internationalization. This is a sector that can give great satisfaction in 'opening Italy to the world' and 'bringing the world to Italy.' Following the European elections, Italy has become one of the most reliable countries at European level, capable of attracting more and more foreign investments."
"The Johnson & Johnson site in Latina, Italy, is undergoing a significant evolution as we enhance our capabilities to serve more patients with innovative products," added Jorge Lopez, general manager of the Latina plant. "It has been designated as a 4IR (Industry 4.0 site) by the World Economic Forum due to our commitment to innovation and sustainability. Times are very exciting for our site."
Last year, Johnson & Johnson Innovative Medicine said it managed 114 clinical trials and collaborated with 993 research centers in Italy. Marcello Cattani, President of Farmindustria, Italy's pharmaceutical trade association declared: "It is not a coincidence that production of the sector exceeded 50 billion euros ($54.5 billion), 49 billion euros of that ($53.4 billion) for export. In Italy, pharmaceutical employment, especially among young people and women, continues to grow, reaching 70,000 workers."
Industrial Info Resources (IIR) is the leading provider of industrial market intelligence. Since 1983, IIR has provided comprehensive research, news and analysis on the industrial process, manufacturing and energy related industries. IIR's Global Market Intelligence (GMI) helps companies identify and pursue trends across multiple markets with access to real, qualified and validated plant and project opportunities. Across the world, IIR is tracking over 200,000 current and future projects worth $17.8 Trillion (USD).
Roughly 125 million euro (US$136 million) will go to capacity upgrades and a capability buildout at its Latina tablet manufacturing site in central Italy. Industrial Info is tracking two projects related to boosting capacity and new equipment additions. Latina plays a key role in Johnson & Johnson's global supply chain network, producing more than four billion tablets every year across 30 different products, with 97% of its production exported. The proposed projects will enable a production capacity increase of more than 25% and will include "innovative projects to support pipeline products and new production technologies", such as a Flex Line, which is designed to more efficiently handle the packaging of small production batches. There will also be a new continuous manufacturing line that will reduce total end-to-end manufacturing time and enable medicines to reach patients more quickly, the company stated.
Johnson & Johnson Innovative Medicine--formally Janssen--employs about 1,370 people in Italy. It said that its total Italian investment, which has included around 50 million euro ($54.6 million) in R&D over the past five years, has averaged 9.2% growth each year between 2019-2023 in Italy, "which is three times greater than the pharmaceutical sector average," it stated, citing a new study by The European House.
The investment was welcomed by the Italian Minister of Enterprises and Made in Italy Adolfo Urso: "Today's press conference demonstrates how the pharmaceutical sector has become a new growth model for Made in Italy, thanks to the impressive investments in research and innovation. This growth is 60% driven by foreign companies and allows the local supply chain to grow and promotes its internationalization. This is a sector that can give great satisfaction in 'opening Italy to the world' and 'bringing the world to Italy.' Following the European elections, Italy has become one of the most reliable countries at European level, capable of attracting more and more foreign investments."
"The Johnson & Johnson site in Latina, Italy, is undergoing a significant evolution as we enhance our capabilities to serve more patients with innovative products," added Jorge Lopez, general manager of the Latina plant. "It has been designated as a 4IR (Industry 4.0 site) by the World Economic Forum due to our commitment to innovation and sustainability. Times are very exciting for our site."
Last year, Johnson & Johnson Innovative Medicine said it managed 114 clinical trials and collaborated with 993 research centers in Italy. Marcello Cattani, President of Farmindustria, Italy's pharmaceutical trade association declared: "It is not a coincidence that production of the sector exceeded 50 billion euros ($54.5 billion), 49 billion euros of that ($53.4 billion) for export. In Italy, pharmaceutical employment, especially among young people and women, continues to grow, reaching 70,000 workers."
Industrial Info Resources (IIR) is the leading provider of industrial market intelligence. Since 1983, IIR has provided comprehensive research, news and analysis on the industrial process, manufacturing and energy related industries. IIR's Global Market Intelligence (GMI) helps companies identify and pursue trends across multiple markets with access to real, qualified and validated plant and project opportunities. Across the world, IIR is tracking over 200,000 current and future projects worth $17.8 Trillion (USD).
